Methotrexate vs azathioprine in chronic sarcoidosis

Adriane D.M. Vorselaars, Wim A. Wuyts, Veronique M.M. Vorselaars,Pieter Zanen, Vera H. Deneer, Michiel Thomeer, Jan C. Grutters

Author address: 

Centre of Interstitial Lung Diseases, Department of Pulmonology, St. Antonius Hospital, Nieuwegein, Netherlands


Background: Although steroids remain the mainstay of therapy in sarcoidosis, chronic use is associated with toxicity. Evidence is missing on which second line therapy is most appropriate. Aim: To compare the effect of methotrexate (MTX) and azathriopine (AZA) in second line treatment of chronic sarcoidosis patients regarding steroid use, lung function and side effects. Methods: This is a retrospective cohort study, reviewing all patients who started MTX or AZA in two Dutch/Belgian tertiary referral centres. Demographic data, steroid use, lung function tests and side effects were noted from initiation until 2 years after or discontinuation. Treatment effect was calculated with a linear mixed model with FEV1, VC, DLCO and prednisone dose changes over time as endpoints. Differences in side effects were calculated with 967;2-tests. Results: 200 patients were included, 145 received MTX and 55 received AZA. Prednisone daily dose decreased with 6.32 mg/year (p

abstract No: 


Full conference title: 

European Respiratory Society Annual Congress
    • ERS 22nd (2012)